Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis

Int J Biochem Cell Biol. 2015 Feb:59:41-51. doi: 10.1016/j.biocel.2014.11.018. Epub 2014 Dec 5.

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) is closely associated with the onset of diabetes and its complications. However, its roles in diabetic retinopathy are unknown. Retinal pigment epithelial (RPE) cells are a crucial component of the outer blood-retina barrier and their death is related to the progression of diabetic retinopathy. Thus, we examined the pathophysiological role of GLP-1R in RPE cell apoptosis. We found that GLP-1R expression was lower in the isolated neuroretina and RPE cells of streptozotocin-treated rats than in vehicle-treated rats. High-glucose treatment also decreased GLP-1R expression in a human RPE cell line (ARPE-19 cells). GLP-1R was silenced in ARPE-19 cells, in order to elucidate the pathophysiological roles of GLP-1R. This increased intracellular reactive oxygen species (ROS) generation and activated p53-mediated Bax promoter and endoplasmic reticulum (ER) stress signaling. We also found that GLP-1R knockdown-mediated p53 expression was regulated by ER stress. Interestingly, antioxidant treatment and peroxiredoxin 1 (Prx1) overexpression attenuated GLP-1R knockdown-induced ER stress signaling and p53 expression. Finally, to confirm that GLP-1R activation has protective effects, ARPE-19 cells were treated with exendin-4, a synthetic GLP-1R agonist. This attenuated high-glucose-induced ROS generation, ER stress signaling, and p53 expression. Collectively, these results indicated that hyperglycemia decreases GLP-1R expression in RPE cells. Such a decrease generates intracellular ROS, which increases ER stress-mediated p53 expression, and subsequently causes apoptosis by increasing Bax promoter activity. Our data suggested that regulation of GLP-1R expression is a promising approach for the treatment of diabetic retinopathy.

Keywords: Diabetic retinopathy; Endoplasmic reticulum stress; Glucagon-like peptide-1 receptor; P53; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis* / drug effects
  • Cell Line
  • Cells, Cultured
  • Down-Regulation* / drug effects
  • Endoplasmic Reticulum Stress / drug effects
  • Exenatide
  • Gene Knockdown Techniques
  • Gene Silencing / drug effects
  • Glucagon-Like Peptide-1 Receptor
  • Glucose / pharmacology
  • Humans
  • Hyperglycemia / metabolism*
  • Intracellular Space / metabolism
  • Models, Biological
  • Peptides / pharmacology
  • Promoter Regions, Genetic / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Reactive Oxygen Species / metabolism
  • Receptors, Glucagon / metabolism*
  • Retinal Pigment Epithelium / pathology*
  • Signal Transduction / drug effects
  • Streptozocin
  • Tumor Suppressor Protein p53 / metabolism
  • Venoms / pharmacology
  • bcl-2-Associated X Protein / genetics

Substances

  • GLP1R protein, human
  • Glp1r protein, rat
  • Glucagon-Like Peptide-1 Receptor
  • Peptides
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Receptors, Glucagon
  • Tumor Suppressor Protein p53
  • Venoms
  • bcl-2-Associated X Protein
  • Streptozocin
  • Exenatide
  • Glucose